Technical Analysis for BCYC - Bicycle Therapeutics plc

Grade Last Price % Change Price Change
grade D 16.32 3.36% 0.53
BCYC closed up 3.36 percent on Monday, August 10, 2020, on 25 percent of normal volume.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Up
Historical BCYC trend table...

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Outside Day Range Expansion 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 3.36%
Inside Day Range Contraction 3.36%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.18%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -1.92%
Oversold Stochastic Weakness -1.92%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Stochastic Buy Signal Bullish 0.00%
Inside Day Range Contraction 0.00%

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Bicycle Therapeutics Limited, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in preclinical studies targeting EphA2; BT8009, which is in preclinical studies targeting Nectin-4; and CD137, an immune cell co-stimulatory molecule that is in preclinical stage, as well as systemically-delivered activators. In addition, it is developing THR-149, a key immune cell co-stimulatory molecule that is in Phase I clinical trials. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, hematology, ophthalmology, and respiratory indications. The company has a clinical trial and license agreement with the Cancer Research Technology Limited and CRUK; and research collaboration agreement with Bioverativ Inc., AstraZeneca AB, and Oxurion NV. The company was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
Medicine Health Biopharmaceutical Life Sciences Diseases Immunology Oncology Tumors Astrazeneca Immune Checkpoint

Is BCYC a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 20.1
52 Week Low 6.2401
Average Volume 50,914
200-Day Moving Average 13.21
50-Day Moving Average 16.79
20-Day Moving Average 17.18
10-Day Moving Average 16.21
Average True Range 1.17
ADX 15.39
+DI 12.29
-DI 15.86
Chandelier Exit (Long, 3 ATRs ) 16.58
Chandelier Exit (Short, 3 ATRs ) 18.77
Upper Bollinger Band 19.44
Lower Bollinger Band 14.91
Percent B (%b) 0.31
BandWidth 26.40
MACD Line -0.22
MACD Signal Line -0.07
MACD Histogram -0.1439
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 17.79
Resistance 3 (R3) 17.63 16.97 17.54
Resistance 2 (R2) 16.97 16.60 17.05 17.46
Resistance 1 (R1) 16.65 16.37 16.81 16.81 17.38
Pivot Point 15.99 15.99 16.08 16.08 15.99
Support 1 (S1) 15.67 15.62 15.83 15.83 15.26
Support 2 (S2) 15.01 15.39 15.10 15.18
Support 3 (S3) 14.69 15.01 15.10
Support 4 (S4) 14.85